help button home button Am J Pathol PCR Enhanced. PCRboost from Biomatrica
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilson, K. S.
Right arrow Articles by Geradts, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, K. S.
Right arrow Articles by Geradts, J.
(American Journal of Pathology. 2002;161:1171-1185.)
© 2002 American Society for Investigative Pathology

Regular Articles

Differential Gene Expression Patterns in HER2/neu-Positive and -Negative Breast Cancer Cell Lines and Tissues

Katherine S. Wilson*, Helen Roberts*, Russell Leek{dagger}, Adrian L. Harris{dagger} and Joseph Geradts{ddagger}

From the Nuffield Department of Clinical Laboratory Sciences,* University of Oxford, Oxford; the Imperial Cancer Research Fund Molecular Oncology Laboratory,{dagger} the John Radcliffe Hospital, Oxford, United Kingdom; and the Department of Pathology and Laboratory Medicine,{ddagger} Roswell Park Cancer Institute, Buffalo, New York

Overexpression of the oncogene HER2/neu (c-erbB-2) occurs in up to 30% of breast cancers and is correlated with reduced survival, especially in node-positive disease. The aim of this study was to identify genes associated with the aggressive phenotype of HER2/neu-positive breast cancer cells using cDNA microarrays. RNA was extracted from three HER2/neu-positive and three HER2/neu-negative breast cancer cell lines. Pooled RNA was hybridized in duplicate to the breast specific microarray filters from Research Genetics containing 5184 unique cDNAs. Subsequently, a similar comparison was performed for pooled RNAs from 10 node-positive, ER-positive invasive ductal carcinomas, half of which were HER2/neu overexpressers. In HER2/neu overexpressing breast cancer cell lines, 90 (1.7%) genes were up-regulated and 46 (0.9%) were down-regulated, compared to cell lines with low HER2/neu protein levels. In contrast, in HER2/neu overexpressing primary breast cancers, more genes were down-regulated (N = 132, 2.5%) than up-regulated (N = 19, 0.4%). Many of the differentially expressed genes have previously not been known to play a role in human neoplasia, and some of them may represent novel tumor suppressor or oncogenes. No genes were up-regulated, and only a small number of genes were down-regulated both in cell lines and in carcinomas with high HER2/neu protein levels. These included transforming acidic coiled-coil containing protein 1, glycogen phosphorylase BB, complement 1q and one EST. The differential expression of select genes was confirmed by Northern blotting (trefoil factor 3) or by immunocytochemistry (glycogen phosphorylase BB, vimentin, KAI1). In an extended validation study, 18 of 41 ER-negative, but none of 46 ER-positive, breast carcinomas were found to express vimentin, and all but one of the vimentin-positive tumors were confined to the HER2/neu-negative subgroup (P = 0.0019). Our findings support an important role of the mammary stroma in determining the clinical breast cancer phenotype.




This article has been cited by other articles:


Home page
 J EndocrinolHome page
S. Raulic, Y. Ramos-Valdes, and G. E DiMattia
Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro
J. Endocrinol., June 1, 2008; 197(3): 517 - 529.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. F. R. Robertson
Fulvestrant (Faslodex(R)) How to Make a Good Drug Better
Oncologist, July 1, 2007; 12(7): 774 - 784.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
E. Martin-Rendon, S. J.M. Hale, D. Ryan, D. Baban, S. P. Forde, M. Roubelakis, D. Sweeney, M. Moukayed, A. L. Harris, K. Davies, et al.
Transcriptional Profiling of Human Cord Blood CD133+ and Cultured Bone Marrow Mesenchymal Stem Cells in Response to Hypoxia
Stem Cells, April 1, 2007; 25(4): 1003 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Dolled-Filhart, L. Ryden, M. Cregger, K. Jirstrom, M. Harigopal, R. L. Camp, and D. L. Rimm
Classification of breast cancer using genetic algorithms and tissue microarrays.
Clin. Cancer Res., November 1, 2006; 12(21): 6459 - 6468.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. G. Madson, D. T. Lynch, K. L. Tinkum, S. K. Putta, and L. A. Hansen
Erbb2 Regulates Inflammation and Proliferation in the Skin after Ultraviolet Irradiation
Am. J. Pathol., October 1, 2006; 169(4): 1402 - 1414.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M.-C. Hsu, H.-C. Chang, and W.-C. Hung
HER-2/neu Represses the Metastasis Suppressor RECK via ERK and Sp Transcription Factors to Promote Cell Invasion
J. Biol. Chem., February 24, 2006; 281(8): 4718 - 4725.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Ostapkowicz, K. Inai, L. Smith, S. Kreda, and J. Spychala
Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor.
Mol. Cancer Ther., February 1, 2006; 5(2): 238 - 245.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Fiegl, S. Millinger, G. Goebel, E. Muller-Holzner, C. Marth, P. W. Laird, and M. Widschwendter
Breast Cancer DNA Methylation Profiles in Cancer Cells and Tumor Stroma: Association with HER-2/neu Status in Primary Breast Cancer
Cancer Res., January 1, 2006; 66(1): 29 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
D. Zhang, L. K. Tai, L. L. Wong, L.-L. Chiu, S. K. Sethi, and E. S. C. Koay
Proteomic Study Reveals That Proteins Involved in Metabolic and Detoxification Pathways Are Highly Expressed in HER-2/neu-positive Breast Cancer
Mol. Cell. Proteomics, November 1, 2005; 4(11): 1686 - 1696.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
R. A. Jolly, K. M. Goldstein, T. Wei, H. Gao, P. Chen, S. Huang, J.-M. Colet, T. P. Ryan, C. E. Thomas, and S. T. Estrem
Pooling samples within microarray studies: a comparative analysis of rat liver transcription response to prototypical toxicants
Physiol Genomics, August 11, 2005; 22(3): 346 - 355.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Huang, J. Groth, K. Sossey-Alaoui, L. Hawthorn, S. Beall, and J. Geradts
Aberrant Expression of Novel and Previously Described Cell Membrane Markers in Human Breast Cancer Cell Lines and Tumors
Clin. Cancer Res., June 15, 2005; 11(12): 4357 - 4364.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Astolfi, L. Landuzzi, G. Nicoletti, C. De Giovanni, S. Croci, A. Palladini, S. Ferrini, M. Iezzi, P. Musiani, F. Cavallo, et al.
Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma
Am. J. Pathol., April 1, 2005; 166(4): 1205 - 1216.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Modlich, H.-B. Prisack, M. Munnes, W. Audretsch, and H. Bojar
Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease
Clin. Cancer Res., October 1, 2004; 10(19): 6418 - 6431.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society for Investigative Pathology.